Printer Friendly

Clinical Data on Aptinyx' NYX-2925 Presented at American Society for Experimental Neurotherapeutics Annual Meeting.

M2 PHARMA-March 12, 2018-Clinical Data on Aptinyx' NYX-2925 Presented at American Society for Experimental Neurotherapeutics Annual Meeting

(C)2018 M2 COMMUNICATIONS

- US-based brain and nervous system disorder treatment developer Aptinyx Inc. has presented preclinical and early-stage clinical data from studies of the company's lead product candidate, NYX-2925, at the 20th annual meeting of the American Society for Experimental Neurotherapeutics, the company said.

The presentation featured results from preclinical studies that further demonstrate efficacy and safety of NYX-2925, Aptinyx's novel modulator of the N-methyl-D-aspartate (NMDA) receptor, in several models of neuropathic pain.

In several preclinical models of neuropathic pain, NYX-2925 demonstrated reproducible and dose-dependent analgesic activity. At doses well in excess of the analgesic dose levels, NYX-2925 did not have adverse effects in safety-pharmacology and toxicology studies.

NYX-2925 had high oral bioavailability and the pharmacokinetics were reproducible and predictable across species.

The presentation also included Phase 1 clinical data outlining the safety, tolerability, and pharmacokinetics of NYX-2925 in healthy volunteers. Once-daily oral dosing with NYX-2925 for seven days produced linear, dose-proportional pharmacokinetics and minimal accumulation in 84 healthy adult volunteers.

NYX-2925 was generally well-tolerated, there were no serious adverse events reported, and no subjects discontinued due to adverse events. Additionally, evaluation of cerebrospinal fluid samples from study participants confirmed that NYX-2925 crosses the blood-brain barrier.

NYX-2925 is an oral, small-molecule NMDA receptor modulator that binds to a novel site on the NMDA receptor and enhances synaptic plasticity to restore normal neural cell function.

Aptinyx is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system.

The company has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate -- rather than block or over-activate -- NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 12, 2018
Words:309
Previous Article:Cyteir Therapeutics Raises USD 29m Financing.
Next Article:ClinOne Releases Online Patient Matching Solution to Improve Access to Clinical Trials.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters